Patents by Inventor Earl Michael Gibbs

Earl Michael Gibbs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors
    Patent number: 6967204
    Abstract: This invention is directed to a method of treating insulin resistance syndrome (IRS), hypertension and/or type 2 diabetes in a mammal comprising administering to said mammal a cGMP PDE9 inhibitor or a pharmaceutical composition thereof. This invention is also directed to such methods wherein said cGMP PDE9 inhibitor is used in combination with other agents to treat IRS, hypertension and/or type 2 diabetes.
    Type: Grant
    Filed: October 29, 2002
    Date of Patent: November 22, 2005
    Assignee: Pfizer Inc
    Inventors: David A. Fryburg, Earl Michael Gibbs
  • Treatment of type 1 diabetes with PDE5 inhibitors
    Publication number: 20040186046
    Abstract: The use of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of Type 1 Diabetes. A method of treating Type 1 Diabetes in an individual suffering from Type 1 Diabetes, which method comprises administering to said individual an effective amount of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 12, 2004
    Publication date: September 23, 2004
    Applicant: Pfizer Inc
    Inventors: Gillian Munro Burgess, Earl Michael Gibbs, Christopher Peter Wayman
  • Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors
    Publication number: 20040023989
    Abstract: This invention is directed to a method of treating insulin resistance syndrome (IRS), hypertension and/or type 2 diabetes in a mammal comprising administering to said mammal a cGMP PDE9 inhibitor or a pharmaceutical composition thereof. This invention is also directed to such methods wherein said cGMP PDE9 inhibitor is used in combination with other agents to treat IRS, hypertension and/or type 2 diabetes.
    Type: Application
    Filed: October 29, 2002
    Publication date: February 5, 2004
    Inventors: David A. Fryburg, Earl Michael Gibbs
  • Treatment of the insulin resistance syndrome
    Publication number: 20030166662
    Abstract: Use of a selective cGMP PDE5 inhibitor or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of the insulin resistance syndrome wherein the insulin resistance syndrome means the concomitant existence in a subject of two or more of dyslipidemia; hypertension; type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity wherein said use can occur alone or in combination with other agents to treat the insulin resistance syndrome or individual aspects of the insulin resistance syndrome.
    Type: Application
    Filed: February 19, 2003
    Publication date: September 4, 2003
    Applicant: Pfizer Inc.
    Inventors: David Albert Fryburg, Earl Michael Gibbs, Nandan Parmanand Koppiker
  • Treatment of the insulin resistance syndrome
    Publication number: 20020165237
    Abstract: Use of a selective cGMP PDE5 inhibitor or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of the insulin resistance syndrome wherein the insulin resistance syndrome means the concomitant existence in a subject of two or more of: dyslipidemia; hypertension; type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity wherein said use can occur alone or in combination with other agents to treat the insulin resistance syndrome or individual aspects of the insulin resistance syndrome.
    Type: Application
    Filed: August 10, 2001
    Publication date: November 7, 2002
    Inventors: David Albert Fryburg, Earl Michael Gibbs, Nandan Parmanand Koppiker